Trial Profile
Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Biomarker; Pharmacodynamics
- Acronyms NO-MI
- 05 Jun 2017 Status changed from not yet recruiting to discontinued.
- 03 Aug 2009 New trial record